Komori
Business Alliance4528ONO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Entered into an exclusive license agreement with U.S.-based Biohaven for the development and commercialization of an "IgG-degrading drug" asset in Japan, South Korea, Taiwan and ASEAN countries

Ono Pharmaceutical entered into a license agreement to exclusively develop and commercialize 3 IgG-degrading drugs currently under development by Biohaven in Japan, South Korea, Taiwan and ASEAN countries. Ono Pharmaceutical will conduct clinical trials, obtain regulatory approval and handle sales in the applicable territories, while paying Biohaven an upfront payment, development milestones and sales-based royalties.

Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
1
US$100 million (US$80 million upfront payment and US$20 million in development milestones)
Wording
Definitive
How definitive the wording is.

Agreements reached under this partnership

Business Alliance
4528ONO PHARMACEUTICAL CO.,LTD.
Alliance partnerBiohaven Ltd.
Details of the alliance
  1. 1

    A license agreement granting exclusive rights to develop and commercialize the assets in Japan, South Korea, Taiwan and ASEAN countries

  2. 2

    We will conduct clinical trials and obtain marketing authorization in Japan, South Korea, Taiwan and ASEAN countries.

  3. 3

    Following regulatory approval, we will be responsible for selling the assets in those territories.

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionA US biotechnology company engaged in the discovery, development and commercialization of therapeutics that have the potential to transform patients’ lives in the areas of immunology, neurology and oncology
LocationNew Haven, Connecticut, US
Impact on Business Performance

The impact on our consolidated results for the fiscal year ending March 2027 is immaterial

Contract Date8 October 2026
Agreements reached under this partnership
ItemDetails
Name of alliance partnerBiohaven Ltd.
Alliance partner's business activitiesA US biotechnology company engaged in the discovery, development and commercialization of therapeutics that have the potential to transform patients’ lives in the areas of immunology, neurology and oncology
Alliance partner's locationNew Haven, Connecticut, US
Type of allianceBusiness Alliance
Details of the allianceA license agreement granting exclusive rights to develop and commercialize the assets in Japan, South Korea, Taiwan and ASEAN countries, We will conduct clinical trials and obtain marketing authorization in Japan, South Korea, Taiwan and ASEAN countries., Following regulatory approval, we will be responsible for selling the assets in those territories.
Contract Date8 October 2026
Impact on Business PerformanceThe impact on our consolidated results for the fiscal year ending March 2027 is immaterial
Items this document does not state (16)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To strengthen the late-stage pipeline in immune and inflammatory diseases and provide new treatment options for patients with Graves’ disease in Japan, South Korea, Taiwan and ASEAN countries.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Entered into an exclusive license agreement with U.S.-based Biohaven for the development and commercialization of an "IgG-degrading drug" asset in Japan, South Korea, Taiwan and ASEAN countries | ONO PHARMACEUTICAL CO.,LTD. (4528) timely disclosure | Komori